Aphios and VivaCell Biotechnology Espana to Develop Novel Class of Compounds for Multiple Sclerosis and CNS Disorders
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
WOBURN, Mass.--(BUSINESS WIRE)--Aphios Corporation, today announced that it has entered into joint Research Collaboration and Commercialization Agreements with VivaCell Biotechnology España S.L., Cordoba, Spain to develop therapeutics for multiple sclerosis and other neurodegenerative diseases of the central nervous system (CNS). Multiple sclerosis (MS), a neurodegenerative disease of the CNS, is one of the main causes of irreversible neurologic disability in young adults. MS is notoriously heterogeneous in terms of clinical manifestations and evolution. The disease affects more than 2 million people worldwide, of which an estimated 400,000 are in the US and 500,000 in Europe. According to the Cleveland Clinic, MS-related health care costs are estimated to be over $10 billion per year in the United States. While progress has been made on developing therapeutics for this debilitating disease, there is still a high unmet need for safe and cost-effective therapeutics that can efficiently cross the blood brain barrier.
Help employers find you! Check out all the jobs and post your resume.
WOBURN, Mass.--(BUSINESS WIRE)--Aphios Corporation, today announced that it has entered into joint Research Collaboration and Commercialization Agreements with VivaCell Biotechnology España S.L., Cordoba, Spain to develop therapeutics for multiple sclerosis and other neurodegenerative diseases of the central nervous system (CNS). Multiple sclerosis (MS), a neurodegenerative disease of the CNS, is one of the main causes of irreversible neurologic disability in young adults. MS is notoriously heterogeneous in terms of clinical manifestations and evolution. The disease affects more than 2 million people worldwide, of which an estimated 400,000 are in the US and 500,000 in Europe. According to the Cleveland Clinic, MS-related health care costs are estimated to be over $10 billion per year in the United States. While progress has been made on developing therapeutics for this debilitating disease, there is still a high unmet need for safe and cost-effective therapeutics that can efficiently cross the blood brain barrier.
Help employers find you! Check out all the jobs and post your resume.